XML 38 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Reporting
6 Months Ended
Jun. 30, 2018
Segment Reporting [Abstract]  
Segment Reporting
 SEGMENT REPORTING
  
Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker (“CODM”), or decision-making group, in deciding how to allocate resources and in assessing performance. Our CODM is our Chief Executive Officer. Our reportable segments include diagnostic and information technology-based products and services for the veterinary market, which we refer to as the Companion Animal Group (“CAG”), water quality products (“Water”) and diagnostic products and services for livestock and poultry health and to ensure the quality and safety of milk and improve dairy efficiency, which we refer to as Livestock, Poultry and Dairy (“LPD”). Our Other operating segment combines and presents products for the human point-of-care medical diagnostics market with our pharmaceutical product line and our out-licensing arrangements.

Certain costs are not allocated to our operating segments and are instead reported under the caption “Unallocated Amounts.” These costs include costs that do not align with one of our existing operating segments or are cost prohibitive to allocate, which primarily consist of our R&D function, regional or country expenses, certain foreign currency revaluation gains and losses on monetary balances in currencies other than our subsidiaries’ functional currency and unusual items. Corporate support function costs (such as information technology, facilities, human resources, finance and legal), health benefits and incentive compensation are charged to our business segments at pre-determined budgeted amounts or rates. Differences from these pre-determined budgeted amounts or rates are captured within Unallocated Amounts.

The following is a summary of segment performance for the three and six months ended June 30, 2018 and 2017 (in thousands):
໿
໿
໿

 
For the Three Months Ended June 30,

 
CAG
 
Water
 
LPD
 
Other
 
Unallocated Amounts
 
Consolidated Total
2018
 
 

 
 

 
 

 
 

 
 

 
 

Revenue
 
$
507,487

 
$
32,658

 
$
34,998

 
$
5,609

 
$

 
$
580,752


 
 
 
 
 
 
 
 
 
 
 
 
Income (loss) from operations
 
$
129,796

 
$
15,122

 
$
6,471

 
$
1,130

 
$
(6,925
)
 
$
145,594

Interest expense, net
 
 
 
 
 
 
 
 
 
 
 
(8,285
)
Income before provision for income taxes
 
 
 
 
 
 
 
 
 
 
 
137,309

Provision for income taxes
 
 
 
 
 
 
 
 
 
 
 
28,629

Net income
 
 
 
 
 
 
 
 
 
 
 
108,680

Less: Net loss attributable to noncontrolling interest
 
 
 
 
 
 
 
 
 
 
 
(11
)
Net income attributable to IDEXX Laboratories, Inc. stockholders
 
 
 
 
 
 
 
 
 
 
 
$
108,691


 
 
 
 
 
 
 
 
 
 
 
 
2017
 
 
 
 
 
 
 
 
 
 
 
 
Revenue
 
$
439,948

 
$
29,424

 
$
33,553

 
$
6,015

 
$

 
$
508,940


 
 
 
 
 
 
 
 
 
 
 
 
Income (loss) from operations
 
$
108,731

 
$
13,653

 
$
5,176

 
$
768

 
$
(5,764
)
 
$
122,564

Interest expense, net
 
 
 
 
 
 
 
 
 
 
 
(7,979
)
Income before provision for income taxes
 
 
 
 
 
 
 
 
 
 
 
114,585

Provision for income taxes
 
 
 
 
 
 
 
 
 
 
 
29,178

Net income
 
 
 
 
 
 
 
 
 
 
 
85,407

Less: Net income attributable to noncontrolling interest
 
 
 
 
 
 
 
 
 
 
 
50

Net income attributable to IDEXX Laboratories, Inc. stockholders
 
 
 
 
 
 
 
 
 
 
 
$
85,357


໿


 
For the Six Months Ended June 30,

 
CAG
 
Water
 
LPD
 
Other
 
Unallocated Amounts
 
Consolidated Total
2018
 
 

 
 

 
 

 
 

 
 

 
 

Revenue
 
$
978,320

 
$
61,801

 
$
67,238

 
$
11,049

 
$

 
$
1,118,408


 
 
 
 
 
 
 
 
 
 
 
 
Income (loss) from operations
 
$
230,194

 
$
27,584

 
$
9,432

 
$
1,628

 
$
(10,200
)
 
$
258,638

Interest expense, net
 
 
 
 
 
 
 
 
 
 
 
(16,980
)
Income before provision for income taxes
 
 
 
 
 
 
 
 
 
 
 
241,658

Provision for income taxes
 
 
 
 
 
 
 
 
 
 
 
43,502

Net income
 
 
 
 
 
 
 
 
 
 
 
198,156

Less: Net income attributable to noncontrolling interest
 
 
 
 
 
 
 
 
 
 
 
14

Net income attributable to IDEXX Laboratories, Inc. stockholders
 
 
 
 
 
 
 
 
 
 
 
$
198,142


 
 
 
 
 
 
 
 
 
 
 
 
2017
 
 
 
 
 
 
 
 
 
 
 
 
Revenue
 
$
843,175

 
$
54,501

 
$
62,870

 
$
10,415

 
$

 
$
970,961


 
 
 
 
 
 
 
 
 
 
 
 
Income (loss) from operations
 
$
188,586

 
$
23,916

 
$
8,978

 
$
1,161

 
$
(7,834
)
 
$
214,807

Interest expense, net
 
 
 
 
 
 
 
 
 
 
 
(15,485
)
Income before provision for income taxes
 
 
 
 
 
 
 
 
 
 
 
199,322

Provision for income taxes
 
 
 
 
 
 
 
 
 
 
 
44,857

Net income
 
 
 
 
 
 
 
 
 
 
 
154,465

Less: Net income attributable to noncontrolling interest
 
 
 
 
 
 
 
 
 
 
 
89

Net income attributable to IDEXX Laboratories, Inc. stockholders
 
 
 
 
 
 
 
 
 
 
 
$
154,376



See “Note 3. Revenue Recognition” for a summary of disaggregated revenue by reportable segment and by major product and service category for the three and six months ended June 30, 2018 and 2017.